Join us at the inaugural Portfolio Strategy & Decision Making for Biopharma Summit - the must-attend event for pharma and biotech leaders seeking to sharpen their portfolio strategies in today’s dynamic market. Gain exclusive insights into leveraging advanced data analytics, forecasting tools, and innovative approaches to enhance decision-making. This summit will showcase real-world case studies […]

Liquid biopsies are revolutionizing clinical trials, emerging as a game-changing diagnostic tool for monitoring molecular residual disease and detecting disease resistance. This breakthrough enables precise patient stratification, ensuring they receive the most effective and safe treatments. The 3rd Liquid Biopsy Surveillance Summit returns as the leading East Coast forum solely dedicated to MRD detection in clinical trials […]

As structural biology tools and screening technologies advance, the GPCR super family continues to be a hot area of drug discovery, with the potential to treat a plethora of diseases. For the first time ever, the GPCRs-Targeted Drug Discovery Summit Europe is coming to London, with the aim of overcoming pharmacology challenges and advancing the […]

The 2nd Cell Therapy for Autoimmune Disease Summit returns to Philadelphia bigger and better after last year’s explosive debut as the only meeting covering every aspect of bringing cell therapies to the autoimmune space. This year’s agenda brings you the opportunity to learn the A-Zs of accelerating your candidates to be the first in the market and finally bring the cure […]

As the field of cell therapy evolves, integrating the latest technologies and robust analytical methods has never been more crucial. Join us at the 6th Cell Therapy Analytical Development Summit to discover how to enhance your analytical strategies and accelerate product development through IND and clinical trials, leading to more efficient regulatory approval. Why Attend? […]

The Personalized Cancer Vaccine Summit (formerly known as the mRNA Cancer Vaccine Summit) returns to Boston bringing together the top industry players developing individualized approaches across several modalities including mRNA, DNA, peptides, viral, dendritic cell and more to share how they are conquering common challenges, developing novel bioinformatic strategies, and achieving clinical efficacy. This is […]

Just 11 years after Emmanuelle Charpentier and Jennifer Doudna’s seminal CRISPR discovery, Casgevy marks the first approved gene-editing therapy, a major milestone for the field. This breakthrough signals the beginning of a revolution in treating genetic diseases, with a rapidly growing pipeline of precision genome-editing techniques emerging. The 5th Genome Editing Therapeutics Summit (formerly the […]

Discover & Develop Selective, Clinically Validated & Novel Covalent Therapeutics to Expand the Targetable Proteome & Non-Cystine Amino Acid Space in Oncology, Immunology & Beyond The covalency renaissance continues as biopharma race to unlock hard-to-target proteins across oncology, immunology and CNS. Yet, key challenges remain in balancing reactivity and sensitivity, de-risking the ligandability of alternative […]

With recent accelerated approval wins, positive clinical trial readouts, progression through clinical pipelines and exciting mergers and acquisitions, it has certainly been an industry-defining year for the rare and genetic renal space. In the context of rapid progress and a mounting desire to propel game-changing novel therapies that will add to the arsenal of therapeutic […]

With Remix Therapeutics joining forces with Roche and Daiichi Sankyo partnering with Depixus, there have been many valuable collaborations entering the RNA-targeting field, accelerating efficacious and selective small molecules targeting RNA directly, RNA-binding proteins, and RNA/protein complexes. Hence, as the go-to meeting for the RNA-targeting small molecule community, the 7th Annual RNA-Targeted Drug Discovery & […]

With the community hailing the latest FDA-approved therapeutic with Novartis’ inhibitor of the alternative complement for PNH, which inhibitor will be the next to harness the complement system for the development of groundbreaking therapies? With assets in nephrology, ophthalmology, neurodegeneration, and inflammation all progressing through to the clinic, the immunology landscape is preparing to be […]

The 4th ADC Target Selection Summit returns to outline approaches to identify and validate novel targets that can be clinically and commercially successful and discuss rationale behind selecting a target to support with the development of future first-in-class ADCs. With sessions led by Almac Discovery, AstraZeneca, Bolt Biotherapeutics, and many other industry leaders, leave this […]

Join industry leaders like Eli Lilly, Merck, Novo Nordisk and Pfizer at the 4th Applied Biocatalysis & Enzyme Engineering Summit (December 10-12, 2024 – Philadelphia, PA). This is your perfect moment to network with enzyme discovery, engineering, biocatalysis, and process chemistry professionals from both industry and academia. Capitalize on Enzyme Evolution through HTP Screening, Advanced Engineering & […]

Join 100+ leading PAT scientists, engineers, process development, CMC, MSAT and quality experts at the 3rd Annual PAT & Real Time Quality Summit. Explore cutting-edge data-driven case studies, engage in dynamic roundtables and deep dive into KOL-led panel debates. This summit is your gateway to staying ahead of the innovation curve, exceeding stakeholder expectations for faster time to market, and unlocking significant […]

Integrating Expertise from Software Development, Quality Assurance, Regulatory Affairs, & Product Teams to Drive Innovation in Alignment with Global Regulatory Guidelines, AI & ML Enabled Software, Cybersecurity, & Agile Methodologies: The European market is capturing 30% of the global medical device field driven by rapid advances in innovative software, AI, and ML. But as medical […]

The 4th mRNA-Based Therapeutics Summit Europe returns to Frankfurt, Germany as the industry’s premier forum dedicated to showcasing the hottest disease targets, never-before-seen pre-clinical and clinical data, and demonstrating key routes to commercial success for mRNA therapy and vaccine R&D pipelines. Whether you’re entering the mRNA arena for the first time or a well-seasoned mRNA veteran, with two dedicated tracks […]

RNAi Therapeutics holds more promise than ever in treating many diseases beyond the liver, with momentum in this field growing stronger than ever. Breakthrough companies such as Argonaute RNA and Kate Therapeutics have secured funding to propel their innovative RNAi candidates and delivery platforms, as well as pharma giants partnering with innovative biotech companies to […]

The 3rd Molecular Glue Drug Development Summit is returning to bring together leaders across biopharma covering the depth and breadth of the molecular glue field from rational discovery to improving toxicity, PKPD, and late-stage development. Don’t miss out on the unparallel learning and networking opportunities on offer at this summit and join 90+ pioneering Directors, […]

Fresh from the reapproval of Roche/Genentech’s Susvimo, positive readouts for sustained release implants, and suprachoroidal delivery revolutionizing gene therapy delivery to the retina, matching the right delivery route to the right drug has become an unavoidable topic for ophthalmology biopharma. The 3rd Ophthalmic Drug Delivery Summit is the premier gathering for the industry to discuss […]

Waves of new models are being validated. A wider industry shift to precision oncology is requiring more specific genetic models. Availability and cost-effectiveness of sequencing and computational tools are enabling better and more accessible characterization of therapeutic pathways than ever before. The challenges and opportunities in preclinical and translational research are constantly evolving, and it […]

Significant breakthroughs in CNS biology, coupled with innovative neuroscience technologies and a more supportive regulatory landscape, have fueled increased investment and pharmaceutical interest in the CNS. With AbbVie, BMS, and Lundbeck making major acquisitions in the last 12 months alone, this wave of deal-making is redemption for biotech who kept the lights on and are […]

In recent industry news, AAV gene therapies are gaining momentum, with groundbreaking achievements like RegenxBio’s RGX-121 trial for Hunter syndrome, demonstrating significant improvements in neurodevelopmental skills. The global AAV therapy market, valued at $1.5 billion in 2023, is projected to skyrocket to $22.3 billion by 2029. However, scaling up production remains a significant challenge, highlighting […]

Advancing Curative Therapies for Autoimmune Diseases  Building on the success of last year’s meeting, the 8th Antigen-Specific Immune Tolerance Summit will bring together 120+ end-to-end experts in immune tolerance for autoimmune diseases. Agenda highlights include: Standardizing the definition and biomarkers of tolerance to inform clinical endpoints for specific disease studies and work towards measurable milestones of efficacy […]

Investors in the cell therapy industry are actively looking into solid tumours, autoimmune indications and novel engineering as the best place to allocate their money and resources. This, along with the recent investments in Enara Bio, ArsenalBio, Kyverna and Artiva signifies that the field is poised to regain momentum. It’s not just investments that are gaining traction. Recent approvals are changing […]

4th mRNA Analytical Development & Quality Control Summit | February 25-27, 2025 Excitement for mRNA therapeutics continues, as RNA technologies are awarded the Nobel Prize for the second year running. Yet, despite optimized analytics, critical quality control methodology and robust assay development leading to efficient approvals and commercialization, knowledge gaps persist in phase-appropriate assays, analyzing […]

The radiopharmaceutical race is on and pharma leaders such as AstraZenca, BMS , Eli Lilly, Novartis and Sanofi are not getting left behind. Bolstering discovery pipelines through acquisitions of preclinical Mariana Oncology, Radionetics and Aktis Oncology, the field is turning to cutting-edge, novel targeting molecules and new targets to address more unmet medical need. With […]

2025 is shaping up to be the ‘bounce back’ year for natural killer therapy. For the first time we are seeing efficacious in-patient data, expansion into autoimmune disease, and combination approaches all take off! So, we are proud to announce the 10th Anniversary Innate Killer Summit returning to San Diego this March, to showcase all […]

Antibody-drug conjugates remain front and centre of the biopharma world. Following Enhertu’s historic agnostic approval in HER2-positive solid tumours and TIVDAK winning full approval, the field has seen a surge in multi-billion-dollar acquisitions, commercialisation deals, and licensing agreements. These developments have enabled the ADC community to make strides in bringing these therapies to earlier-line treatments […]

In the current cell therapy landscape, where funding is tight and clinical development a priority, developing robust potency assays is critical to avoid costly delays. Introducing the 4th Cell Therapy Potency Assay Summit, uniting AD, QC and regulatory experts, this summit works to design potency assays that not only conform to changing guidelines but also streamline […]

Expanded Access Programs (EAPs) are increasingly recognized as an ethical imperative in modern healthcare. More companies are opening EAPs to provide critical therapies to patients who would otherwise lack access. However, challenges persist, especially when navigating the complex regulatory landscape of global programs. From country-specific regulations to post-trial access, managing global supply chains, importation, licensing, […]